Deals
Deals dated after 30 September 2026 are still being collected.
Columns
7 of 7 deals
| Advisers | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 2026 | Vestmark | – | Envestnet | Acquisition | Legal adviser to Vestmark (target) | Announced | – | Wealthtech+2 | Ropes & Gray (buy-side)UBS (buy-side)Goldman Sachs (buy-side)RBC Capital Markets (buy-side)J.P. Morgan (buy-side)Morgan Stanley (buy-side)Raymond James (sell-side)Berenson & Company (sell-side) | Envestnet acquisition of Vestmark |
| Jul 2026 | Giant Eagle | – | The Kroger Co. | Acquisition | Legal adviser to Giant Eagle (target) | Announced | 1,250.0 | Food Retail+1 | RBC Capital Markets (buy-side)Jones Day (buy-side)Wells Fargo Securities (sell-side)Troutman Pepper Locke (sell-side) | The Kroger Co. acquisition of Giant Eagle |
| Apr 2026 | Hemab Therapeutics Holdings | – | – | IPO | Legal adviser to the issuer | Announced | 301.5 | Biotech+1 | Goldman Sachs (lead manager)Jefferies (lead manager)Evercore (lead manager)Wedbush Securities (lead manager)Goodwin (lead manager) | Hemab Therapeutics Holdings IPO |
| Mar 2026 | Apellis Pharmaceuticals | – | Biogen | Acquisition | Legal adviser to Apellis Pharmaceuticals (target) | Announced | 5,600.0 | Biotech+2 | Lazard (buy-side)Evercore (sell-side)Wachtell, Lipton, Rosen & Katz (sell-side)Cravath, Swaine & Moore (buy-side) | Biogen acquisition of Apellis Pharmaceuticals |
| Mar 2026 | UpSwell Marketing | – | Mountaingate Capital | Acquisition | Legal adviser to Mountaingate Capital (acquirer) | Completed | – | Advertising and marketing | BrightTower (sell-side) | Mountaingate Capital acquisition of UpSwell Marketing |
| Jan 2026 | Mersana Therapeutics | – | Day One Biopharmaceuticals | Acquisition | Legal adviser to Mersana (target) | Completed | – | Biotech+2 | Gordon Dyal & Co. (buy-side)Fenwick & West (buy-side)TD Securities (sell-side) | Day One Biopharmaceuticals acquisition of Mersana Therapeutics |
| Dec 2025 | Generation Bio Co. | – | XRA 7 Corp. | Acquisition | Legal adviser to Generation Bio Co. (target) | Announced | – | Biotech+1 | TD Securities (sell-side)Gibson Dunn (buy-side) | XRA 7 Corp. acquisition of Generation Bio Co. |
Activity
By announcement date; raisings and IPOs by their own date.
Sector of the business bought or funded.
Disclosed value in US dollars.
Most often across the table
- RBC Capital Markets2 dealsCompare
- Gibson Dunn
1 dealCompare - Gordon Dyal & Co.1 dealCompare
- Fenwick & West1 dealCompare
- Lazard
1 dealCompare - Cravath, Swaine & Moore
1 dealCompare - BrightTower1 dealCompare
- Jones Day
1 dealCompare
Firms advising the other side of the same deals.